Cover Image
市場調查報告書

單回使用生物反應器市場

Single-use Bioreactors Market, 2014 - 2024

出版商 ROOTS ANALYSIS 商品編碼 300600
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
單回使用生物反應器市場 Single-use Bioreactors Market, 2014 - 2024
出版日期: 2014年04月23日 內容資訊: 英文 130 Pages
簡介

全球單回使用生物反應器市場預測今後以兩位數繼續成長。"單回使用技術"是1970年代使用小瓶與移液管所產生的概念,此後急速擴展。單回使用生物反應器的主要優點是沒有必要沖洗和殺菌這點。由於與傳統不鏽鋼製生物反應器相比不需要殺菌和沖洗等必要設備,可節約時間和削減前期投資額,受全世界的製藥公司和受託製造廠商喜愛。

本報告提供單回使用生物反應器市場相關調查、歷史概要、與傳統的不鏽鋼製生物反應器的比較、參與企業的簡介、今後的複數的預測方案,為您概述為以下內容。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 概要
  • 歷史的發展
  • 目前環境
    • 許多選項
    • 為何單回使用生物反應器更好
    • 主要課題
    • 傳統的不鏽鋼製和單回使用生物反應器的比較
    • 單回使用生物反應器的種類
    • 單回使用生物反應器的用途
  • 未來預測
    • 今後也繼續成長
    • 今後登場的新企業
    • 細胞治療
    • 其他的用途

第4章 市場概要

  • 概要
  • 單回使用生物反應器的優點
  • 促進成長要素
  • 競爭環境
  • 聯盟

第5章 簡介

  • Sartorius Group
  • GE Healthcare Life Sciences
  • Applikon
  • Thermo Fisher Scientific
  • Merck Millipore
  • Eppendorf
  • PBS Biotech
  • Lution Biotech
  • CerCell
  • ATMI

第6章 未來市場方案

  • 方法
  • 方案定義
  • 方案的結果
  • 比較摘要

第7章 SWOT分析

第8章 採訪概要

第9章 結論

第10章 附錄1

第11章 附錄2

圖表

目錄
Product Code: RA10013

There is widespread optimism that the single-use bioreactors market is likely to continue its double digit growth in the future. The concept of "single-use technology", which started in 1970s with the use of vials and pipettes, has emerged rapidly over the last decade. Today, this term surrounds a wide range of primarily plastic disposable technologies that are suitable for a wide variety of scales, from upscale bioprocessing to final formulation and filling. These can be found in various manufacturing processes and a number of important applications.

A major advantage of single-use bioreactors is that they do not require cleaning or sterilisation. The bags involved in the process can be disposed and replaced by new bags. This lowers the chances of cross-contamination, making them more efficient. Compared to conventional stainless steel bioreactors, single-use bioreactors don't require an extensive piping infrastructure and / or systems to support sterilisation in place (SIP) and cleaning in place (CIP) requirements. This saves a lot of time and upfront capital investment, making single-use bioreactors a preferred option for pharma / contract manufacturers worldwide.

The technology is gradually penetrating mainstream commercial manufacturing in the biopharmaceuticals industry. The growth of single-use bioreactors is evident by the wide range of equipment sizes available in the market today. Many companies have already transitioned from conventional bioreactors to single use bioreactors; others have firmed up their plans to migrate to single-use technology in multiple phases.

Synopsis

The 'Single-use Bioreactors Market, 2014 - 2024 ' report provides an extensive study of this industry, specifically focusing on all the companies manufacturing single-use bioreactors, their applications and the likely future evolution. Single-use bioreactors have tremendous potential: they require less space for production, one-third time for installation and, most importantly, offer a better product yield than the conventional stainless steel bioreactors. The report covers various aspects impacting the industry, such as, technological progress, evolving product portfolios, key challenges, industry partnerships and the likely future roadmap.

The base year for the report is 2013. The report provides multiple forecast scenarios for the period 2014 - 2024. These scenarios are based on a number of parameters, such as, the future growth of overall biopharmaceuticals industry and likely adoption of single-use technology vis-à-vis stainless steel bioreactors. Amongst other elements, we have discussed key drivers behind the likely growth of single-use bioreactors market and identified avenues of growth for the future. One of the key objectives of the report is to provide a holistic market landscape of single-use bioreactors commercially available; this is presented in detail in various sections of the report.

Example Highlights

  • 1. Single-use bioreactors are already being deployed for high density cell culture applications (monoclonal antibodies, recombinant proteins, vaccines etc.); newer application areas being researched include stem cells and personalised medicine.
  • 2. We identified 17 manufacturers offering around 80-90 models of single-use bioreactors with working volumes ranging from as low as few millilitres to up to 2000L.
  • 3. Manufacturing collaborations and acquisitions are rapidly changing the landscape; amongst the 50 odd partnerships we looked at, around 25% were manufacturing collaborations and an additional 25% were mergers / acquisitions.
  • 4. Quite recently, many start-ups have sprung up; examples include CerCell, PBS Biotech, Cellexus Limited; these start-ups have launched single-use bioreactors with innovative features and are likely to play an increasingly important role in the future.
  • 5. The overall industry could grow close to USD 1 billion in a few years' time; however, this will be driven to a certain extent by the overall growth of the biopharmaceuticals' market. Emergence of new technologies is likely to provide the necessary impetus to fuel future growth.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the single-use bioreactors market is headed in the mid-long term.

Chapter 3 provides a general introduction to single-use bioreactors. We have discussed, in detail, the origins of single-use bioreactors and recent developments which have shaped the industry so far. The chapter also elaborates on the current and future applications, and the challenges which have to be overcome before wider adoption of the technology takes place.

Chapter 4 provides an overview of the single-use bioreactors market with respect to the available technologies and companies active in the field. The analysis also identifies key industry partnerships which have recently taken place and the key drivers which are likely to determine the future growth.

Chapter 5 offers a comprehensive review of the major single-use bioreactors which have been made available by leading companies in the market. We present profiles of ten such bioreactors including their key features, usage mechanism, applications, recent partnerships and competitive landscape.

Chapter 6 presents a scenario based approach to identify the future evolution of the industry. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present four different tracks of industry's evolution.

Chapter 7 provides our analysis of the strengths, weaknesses, opportunities and threats in the single-use bioreactors market, capturing the key elements likely to influence future growth.

Chapter 8 is a collection of transcripts of interviews conducted during the course of this study.

Chapter 9 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview
  • 3.2. Historical Evolution
  • 3.3. Current Landscape
    • 3.3.1. Many Options to Choose From
    • 3.3.2. Why Single Use Bioreactors are Better?
    • 3.3.3. Key Known Challenges
      • 3.3.3.1. Lack of Advanced Technology
      • 3.3.3.2. Limited Batch Size
      • 3.3.3.3. Lack of Standardisation
      • 3.3.3.4. Lengthy Customisation Process
      • 3.3.3.5. Performance vis-à-vis Conventional Bioreactors
      • 3.3.3.6. Compatibility with Conventional Bioreactors
    • 3.3.4. Comparison Between Conventional Stainless Steel Bioreactor and Single Use Bioreactor
    • 3.3.5. Types of Single-use Bioreactors
    • 3.3.6. Applications of Single Use Bioreactors
  • 3.4. Future Prospects
    • 3.4.1. Continued Growth of Single-use Bioreactors
    • 3.4.2. New Companies Coming up with Advanced Single-use Bioreactors
    • 3.4.3. Cell Therapeutics
    • 3.4.4. Other Upcoming Applications

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Advancements in Single-use Bioreactors
    • 4.2.1. Production of Stem Cells
    • 4.2.2. Single Use Bioreactor for 3D Cell Growth
    • 4.2.3. Opening Up New Markets
    • 4.2.4. Better and Efficient Process
  • 4.3. Growth Drivers
    • 4.3.1. Market Factors
    • 4.3.2. Advancements in Technology
    • 4.3.3. Product Considerations
    • 4.3.4. The 'Economic Advantage'
  • 4.4. Competitive Landscape
  • 4.5. Partnerships
    • 4.5.1. Number of Partnerships have Increased Over Time
    • 4.5.2. Sartorius Leads the Partnership Activity
    • 4.5.3. Most Partnerships are Manufacturing Collaborations

5. PROFILES

  • 5.1. Sartorius Group
    • 5.1.1. Company Overview
    • 5.1.2. Single-use Bioreactors: Product Portfolio
      • 5.1.2.1. BIOSTAT STR: Key Features
      • 5.1.2.2. Usage Mechanism
      • 5.1.2.3. Applications
    • 5.1.3. Recent Partnerships / Collaborations
      • 5.1.3.1. Acquisition of TAP Biosystems Group
      • 5.1.3.2. Collaboration with Sudpack Medica AG
      • 5.1.3.3. Collaboration with Stedim Biosystems
    • 5.1.4. Competitive Landscape
      • 5.1.4.1. BIOSTAT STR
      • 5.1.4.2. BIOSTAT RM
      • 5.1.4.3. UniVessel SU
      • 5.1.4.4. BIOSTAT ORB
    • 5.1.5. Future Outlook
  • 5.2. GE Healthcare Life Sciences
    • 5.2.1. Company Overview
    • 5.2.2. Single-use Bioreactors: Product Portfolio
      • 5.2.2.1. XDR 50-2000: Key Features
      • 5.2.2.2. Usage Mechanism
      • 5.2.2.3. Applications
    • 5.2.3. Recent Partnerships / Collaborations
      • 5.2.3.1. Acquisition of Xcellerex
      • 5.2.3.2. Licensing Agreement with Sartorius
    • 5.2.4. Competitive Landscape
    • 5.2.5. Future Development Plans
  • 5.3. Applikon
    • 5.3.1. Company Overview
    • 5.3.2. Single-use Bioreactors: Product Portfolio
      • 5.3.2.1. AppliFlex: Key Features
      • 5.3.2.2. Usage Mechanism
      • 5.3.2.3. Applications
    • 5.3.3. Recent Partnerships / Collaborations
      • 5.3.3.1. Collaboration with Thermo Fisher Scientific
      • 5.3.3.2. Collaboration with Millipore
    • 5.3.4. Competitive Landscape
    • 5.3.5. Future Development Plans
  • 5.4. Thermo Fisher Scientific
    • 5.4.1. Company Background
    • 5.4.2. Single-use Bioreactors: Product Portfolio
      • 5.4.2.1. Water Jacket HyClone Single-use Bioreactors: Key Features
      • 5.4.2.2. Usage / Mechanism
      • 5.4.2.3. Key Applications
    • 5.4.3. Recent Partnerships / Collaborations
    • 5.4.4. Competitive Landscape
    • 5.4.5. Future Outlook
  • 5.5. Merck Millipore
    • 5.5.1. Company Overview
    • 5.5.2. Single-use Bioreactors: Product Portfolio
      • 5.5.2.1. Mobius CellReady: Key Features
      • 5.5.2.2. Usage Mechanism
      • 5.5.2.3. Applications
    • 5.5.3. Recent Partnerships / Collaborations
      • 5.5.3.1. Collaboration with Applikon
      • 5.5.3.2. Acquisition by Merck
    • 5.5.4. Competitive Landscape
    • 5.5.5. Future Development Plans
  • 5.6. Eppendorf
    • 5.6.1. Company Overview
    • 5.6.2. Single-use Bioreactors: Product Portfolio
      • 5.6.2.1. CelliGen BLU: Key Features
      • 5.6.2.2. Usage Mechanism
      • 5.6.2.3. Applications
    • 5.6.3. Recent Partnerships / Collaborations
      • 5.6.3.1. Eppendorf - New Brunswick
      • 5.6.3.2. New Brunswick - Pall Corporation
      • 5.6.3.3. Eppendorf - DASGIP
    • 5.6.4. Competitive Landscape
    • 5.6.5. Future Outlook
  • 5.7. PBS Biotech
    • 5.7.1. Company Overview
    • 5.7.2. Single-use Bioreactors: Product Portfolio
      • 5.7.2.1. Key Features
      • 5.7.2.2. Usage Mechanism
      • 5.7.2.3. Applications
    • 5.7.3. Recent Partnerships / Collaborations
    • 5.7.4. Competitive Landscape
    • 5.7.5. Future Outlook
  • 5.8. CELLution Biotech
    • 5.8.1. Company Overview
    • 5.8.2. Single-use Bioreactors: Product Portfolio
      • 5.8.2.1. CELL-tainer 20: Key Features
      • 5.8.2.2. Usage Mechanism
      • 5.8.2.3. Applications
    • 5.8.3. Recent Partnerships / Collaborations
      • 5.8.3.1. Collaboration with Lonza
      • 5.8.3.2. Collaboration with Charter Medical
    • 5.8.4. Competitive Landscape
  • 5.9. CerCell
    • 5.9.1. Company Overview
    • 5.9.2. Single-use Bioreactors: Product Portfolio
      • 5.9.2.1. CellVessel Config SUB: Key Features
      • 5.9.2.2. Usage Mechanism
      • 5.9.2.3. Applications
    • 5.9.3. Recent Partnerships / Collaborations
    • 5.9.4. Competitive Landscape
    • 5.9.5. Future Development Plans
  • 5.10. ATMI
    • 5.10.1. Company Overview
    • 5.10.2. Single-use Bioreactors: Product Portfolio
      • 5.10.2.1. Integrity Xpansion: Key Features
      • 5.10.2.2. Usage Mechanism
      • 5.10.2.3. Applications
    • 5.10.3. Recent Partnerships / Collaborations
      • 5.10.3.1. Acquisition by Pall Corporation
      • 5.10.3.2. Acquisition of LevTech
    • 5.10.4. Competitive Landscape
    • 5.10.5. Future Development Plans

6. FUTURE MARKET SCENARIOS

  • 6.1. Overview
  • 6.2. Methodology
  • 6.3. Scenario Definitions
  • 6.4. Scenario Results
    • 6.4.1. The Bearish Scenario
    • 6.4.2. The Status Quo Scenario
    • 6.4.3. The Bullish Scenario
    • 6.4.4. The Ambitious Scenario
  • 6.5. Comparative Summary

7. SWOT ANALYSIS

  • 7.1. Overview
  • 7.2. Strengths
    • 7.2.1. Ease of Use
    • 7.2.2. Relatively Cost Effective
    • 7.2.3. Many Applications
  • 7.3. Weaknesses
    • 7.3.1. Lack of Standardisation
    • 7.3.2. Lack of Established Experience
    • 7.3.3. Scope of Further Technological Improvements
  • 7.4. Opportunities
    • 7.4.1. Ongoing consolidations / collaborations
    • 7.4.2. Emergence of New Applications
  • 7.5. Threats
    • 7.5.1. Significant Sunk Cost in Replacing Legacy Systems
    • 7.5.2. Potential Pushback from Companies Manufacturing Stainless Steel Equipment

8. INTERVIEW TRANSCRIPTS

9. CONCLUSION

  • 9.1. Benefits will Drive Increased Adoption
  • 9.2. Manufacturing Collaborations and Acquisitions are Rapidly Changing the Market Landscape
  • 9.3. New Technologies Emerging for Mixing Components
  • 9.4. Challenges Exist but Likely to be Overcome in the Future
  • 9.5. The Overall Opportunity, Though Huge, Will have to be Tapped

10. Appendix 1: Tabulated Data

11. Appendix 2: List of Companies and Organisations

List of Figures

  • Figure 3.1 Brief History of Single-use Bioreactors
  • Figure 3.2 Energy Consumption: Conventional Stainless Steel Bioreactors vs. Single-use Bioreactors (Mega joules)
  • Figure 3.3 Water Consumption: Conventional Stainless Steel Bioreactors vs. Single-use Bioreactors (Kilolitres)
  • Figure 4.1 Single-use Bioreactors: The Growth Drivers
  • Figure 4.2 Single-use Bioreactors: Distribution by Type of Motion
  • Figure 4.3 Competitive Landscape: Distribution by Type of Company
  • Figure 4.4 Single-use Bioreactor Manufacturers: Emergence of Start-ups
  • Figure 4.5 Increasing Trend of the Partnerships every year
  • Figure 4.6 Single-use Bioreactors: Leading Players by Partnership Activity
  • Figure 4.7 Single-use Bioreactors: Distribution by Type of Partnership
  • Figure 5.1 Sartorius Group: Portfolio of Single-use Bioreactors
  • Figure 5.2 XDR: Competitive Landscape
  • Figure 5.3 HyClone: Competitive Landscape
  • Figure 5.4 ATMI: Portfolio of Single-use Bioreactors
  • Figure 6.1 Future Market Scenarios: Description
  • Figure 6.2 Single-use Bioreactors: Future Evolution under 'Bearish' Scenario, Short-Mid Term (USD Billion)
  • Figure 6.3 Single-use Bioreactors: Future Evolution under 'Bearish' Scenario, Long Term (USD Billion)
  • Figure 6.4 Single-use Bioreactors: Growth Rates under 'Bearish' Scenario (%)
  • Figure 6.5 Single-use Bioreactors: Future Evolution under 'Status Quo' Scenario, Short-Mid Term (USD Billion)
  • Figure 6.6 Single-use Bioreactors: Future Evolution under 'Status Quo' Scenario, Long Term (USD Billion)
  • Figure 6.7 Single-use Bioreactors: Growth Rates under 'Status Quo' Scenario (%)
  • Figure 6.8 Single-use Bioreactors: Future Evolution under 'Bullish' Scenario, Short-Mid Term (USD Billion)
  • Figure 6.9 Single-use Bioreactors: Future Evolution under 'Bullish' Scenario, Long Term (USD Billion)
  • Figure 6.10 Single-use Bioreactors: Growth Rates under 'Bullish' Scenario (%)
  • Figure 6.11 Single-use Bioreactors: Future Evolution under 'Ambitious' Scenario, Short-Mid Term (USD Billion)
  • Figure 6.12 Single-use Bioreactors: Future Evolution under 'Ambitious' Scenario, Long Term (USD Billion)
  • Figure 6.13 Single-use Bioreactors: Growth Rates under 'Ambitious' Scenario (%)
  • Figure 6.14 Market Scenarios: Comparative Positioning (USD Billion)

List of Tables

  • Table 2.1 List of bioreactors with working volume between 0L - 50L
  • Table 2.2 List of bioreactors with working volume between 50L - 2000L
  • Table 2.3 Single-use Bioreactors: Matrix of Cell Culture Types
  • Table 3.1 Comparison between Conventional and Single use Bioreactors
  • Table 4.1 List of Single-use Bioreactors
  • Table 4.2 Competitive Landscape: List of Companies
  • Table 4.3 Single-use Bioreactors: List of Partnerships
  • Table 5.1 Sartorius Group: Key Characteristics of Single-use Bioreactors
  • Table 5.2 BIOSTAT STR: Available Models
  • Table 5.3 BIOSTAT STR: Competitive Landscape
  • Table 5.4 BIOSTAT RM: Competitive Landscape
  • Table 5.5 UniVessel SU: Competitive Landscape
  • Table 5.6 GE Healthcare Life Sciences: Key Characteristics of Single-use Bioreactors
  • Table 5.7 XDR 50-2000: Available Models
  • Table 5.8 Applikon: Key Characteristics of Single-use Bioreactors
  • Table 5.9 AppliFlex: Available Models
  • Table 5.10 AppliFlex: Competitive Landscape
  • Table 5.11 CellReady: Competitive Landscape
  • Table 5.12 Thermo Fisher Scientific: Key characteristics of Single-use Bioreactors
  • Table 5.13 Water Jacket HyClone Single-use Bioreactors: Available Models
  • Table 5.14 Merck Millipore: Key characteristics of Single-use Bioreactors
  • Table 5.15 Mobius CellReady: Available Models
  • Table 5.16 Mobius CellReady Bioreactor Systems: Competitive Landscape
  • Table 5.17 Eppendorf: Key Characteristics of Single-use Bioreactors
  • Table 5.18 CelliGen BLU: Available models
  • Table 5.19 CelliGen BLU: Other Common Parameters
  • Table 5.20 CelliGen BLU, 5L: Competitive Landscape
  • Table 5.21 CelliGen BLU, 14L: Competitive Landscape
  • Table 5.22 CelliGen BLU, 50L: Competitive Landscape
  • Table 5.23 PBS Biotech: Portfolio of Single-use Bioreactors
  • Table 5.24 PBS Biotech Single-use Bioreactors: Competitive Landscape
  • Table 5.25 CELLution Biotech: Key Characteristics of Single-use Bioreactors
  • Table 5.26 CELL-tainer 20: Physical Parameters
  • Table 5.27 CELL-tainer: Competitive Landscape
  • Table 5.28 CerCell: Portfolio of Single-use Bioreactors - CellVessel Config SUB
  • Table 5.29 CerCell: Portfolio of Single-use Bioreactors - BactoVessel Config SUF
  • Table 5.30 CerCell: Competitive Landscape
  • Table 5.31 ATMI: Key Characteristics of Single-use Bioreactors
  • Table 5.32 Integrity Xpansion: Available models
  • Table 7.1 SWOT Analysis of Single-use Bioreactors Market
  • Table 10.1 Future Evolution under 'Bearish' Scenario, Short-Mid Term (USD Billion)
  • Table 10.2 Future Evolution under 'Bearish' Scenario, Long Term (USD Billion)
  • Table 10.3 Future Evolution under 'Status Quo' Scenario, Short-Mid Term (USD Billion)
  • Table 10.4 Future Evolution under 'Status Quo' Scenario, Long Term (USD Billion)
  • Table 10.5 Future Evolution under 'Bullish' Scenario, Short-Mid Term (USD Billion)
  • Table 10.6 Future Evolution under 'Bullish' Scenario, Long Term (USD Billion)
  • Table 10.7 Future Evolution under 'Aggressive' Scenario, Short-Mid Term (USD Billion)
  • Table 10.8 Future Evolution under 'Aggressive' Scenario, Long Term (USD Billion)

List of Companies

The following companies and organisations have been mentioned in the report.

  • 1. 3HBiomedical
  • 2. ABEC
  • 3. AmProtein
  • 4. Applikon
  • 5. Artelis
  • 6. ATMI Life Sciences
  • 7. Avid Bioservices
  • 8. Bayer Technology Services
  • 9. bbi-biotech
  • 10. Bioceros
  • 11. Boehringer Ingelheim
  • 12. BPTC
  • 13. Broadley James
  • 14. CarouCELL
  • 15. Catalent Pharma Solutions
  • 16. Cell Technology Group, School of Biotechnology, Royal Institute of Technology, KTH.
  • 17. Cellexus Limited
  • 18. CELLution Biotech
  • 19. CerCell
  • 20. CESCO
  • 21. Charter Medical
  • 22. CMC Biologics
  • 23. Cobra Biologics
  • 24. Colder Products Co.
  • 25. Cytovance Biologics
  • 26. Dasgip
  • 27. Department of Systems biology, Danish Technical university (DTU)
  • 28. DMT GmbH
  • 29. Dync B.V.
  • 30. Electrospinning Company
  • 31. Eppendorf
  • 32. ExcellGene
  • 33. ExpreS2ion Biotechnologies
  • 34. Finesse
  • 35. Fujifilm Diosynth Biotechnologies
  • 36. G & G Technologies
  • 37. Gallus Biologics
  • 38. GE Healthcare Life Sciences
  • 39. GreenVax
  • 40. Halix
  • 41. Hamilton
  • 42. Hynetics
  • 43. Infors HT
  • 44. Integra Biosciences
  • 45. Integrated Product Services
  • 46. Integrity CMI
  • 47. Invitrogen
  • 48. KBI BioPharma
  • 49. Kuhner shaker
  • 50. Kungliga Tekniska Högskolan(Stockholm)
  • 51. Laureate Pharma
  • 52. Levtech
  • 53. Lonza
  • 54. Meissner Products
  • 55. Merck KGaA
  • 56. Mibelle Biochemistry
  • 57. Millipore Corporation
  • 58. Nestle
  • 59. Advantapure
  • 60. New Brunswick
  • 61. Novartis Pharma
  • 62. Novavax Inc.
  • 63. Pall Corporation
  • 64. PBS Biotech
  • 65. PharmaTech
  • 66. Pierre Guerin
  • 67. Polestar Technologies
  • 68. Presens Precision Sensing GmbH
  • 69. Pristine Bioproduction
  • 70. ProBioGen
  • 71. Raumedic
  • 72. Refine Technology
  • 73. Roche Diagnostics GmbH
  • 74. SAFC Biosciences
  • 75. Sanisure
  • 76. Sartorius-Stedim Biosystems
  • 77. School of Life Sciences and Facility Management (IBT), Switzerland
  • 78. Scilog
  • 79. Scrum Inc.
  • 80. Shire
  • 81. Single-use Processing systems
  • 82. Solaris Group
  • 83. Stobbe Tech A/S
  • 84. Sudpack Medica AG
  • 85. Svanholm
  • 86. Synthecon
  • 87. TAP Biosystems
  • 88. Tarom Applied Technologies
  • 89. Technical University, Berlin
  • 90. Thermo Fisher Scientific
  • 91. United Therapeutics
  • 92. Wave Biotech AG
  • 93. Wave Biotech LLC
  • 94. WuXiPharma Tech
  • 95. Xcellerex
Back to Top